Truist analyst Asthika Goonewardene is “encouraged” by the data Merus presented today on petosemtamab in combination with pembrolizumab and states that “while this may not be as ‘full’ of a look as we hoped,” the firm is confident the key charts are coming at the ASCO presentation. The firm, which looks forward to more details at ASCO and further follow-up in 2025, keeps a Buy rating and $69 price target on Merus shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus data coming early nothing to be worried about, says Truist
- Merus abstract shows ‘stellar potential’ of petosemtamab, says H.C. Wainwright
- Merus price target raised to $61 from $52 at BofA
- Merus announces publication of abstract on Petosemtamab at ASCO
- Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting